Technology Search

Order Results:

Your search returned '10' results

  • MICRO SU-8 CHAMBER FOR PCR AND FLUORESCENT REAL TIME DETECTION OF Salmonella spp. DNA

    Agency: Osteba

    Name: MicroLAB Detect

    Technology Type: Device Diagnostics

    Patient Indications: Patients with suspected salmonella food poisoning.

    Entered On: January 5 2010

  • Orencia (Abatacept) for rheumatoid arthritis (RA)

    Agency: DMTP

    Name: Orencia (Abatacept) for rheumatoid arthritis (RA)

    Technology Type: Drug

    Patient Indications: For the treatment of moderate - severe rheumatoid arthritis (RA) in adult patients who have insufficient response or intolerance to other anti-rheumatic drugs including at least one tumor-necrosis factor inhibitor.

    Entered On: January 6 2010

  • Pixantrone dimaleate for relapsed or refractory non-Hodgkin’s lymphoma, third or fourth line.

    Agency: NHSC

    Name: Pixantrone

    Technology Type: Drug

    Patient Indications: Non-Hodgkin’s lymphoma (NHL) - relapsed or refractory aggressive, third or fourth line, monotherapy.

    Entered On: January 7 2010

    View Website

  • vProtect luminal shield coronary stent system for vulnerable plaques

    Agency: NHSC

    Name: vProtect luminal shield coronary stent system.

    Technology Type: Device

    Patient Indications: Patients with soft, atherosclerotic lesions that may be vulnerable to rupture: •myocardial infarction (MI) - treatment of patients who have had a MI, or to prevent MI in patients with vulnerable plaques. •acute coronary syndrome (ACS) - to treat thin-capped, rupture-prone plaques.

    Entered On: January 8 2010

  • Fluocinolone acetonide intravitreal insert (Iluvien) for diabetic macular oedema

    Agency: NHSC

    Name: Fluocinolone acetonide intravitreal insert

    Technology Type: Drug

    Patient Indications: Diabetic macular oedema.

    Entered On: January 15 2010

    View Website

  • Eucreas (Vildagliptin + Metformin) for the treatment of diabetes

    Agency: DMTP

    Name: Eucreas (Vildagliptin + Metformin)

    Technology Type: Drug

    Patient Indications: Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glucose control at the maximally tolerated dose of oral metformin alone or metformin + Vildagliptin in separate tablets.

    Entered On: January 17 2010

  • Prepandemic H5N1 influenza vaccines

    Agency: AETSA

    Name: Bk-PifaTM, HokkenTM, Fluval H5N1TM, PanfluTM, PrepandrixTM

    Technology Type: Drug

    Patient Indications: SAGE recommendations [1]: Strongly recommended: Persons should not carry out their functions unless they are vaccinated. Recommended: Persons are encouraged to be vaccinated. May be made available: Responsible authorities should assess whether licensed human H5N1 influenza vaccines might be made available, without encouraging persons to be vaccinated. This does not imply that vaccine should be provided free of charge.

    Entered On: January 19 2010

  • Diagnostic test for tyrosine kinase inhibitors treatment for non-small-cells lung cancer (NSCLC)

    Agency: Agenas (COTE)

    Name: TheraScreen EGFR29

    Technology Type: Diagnostics

    Patient Indications: The technology aims to identify mutations in the EGFR (epidermal growth factor receptor) gene in patients with Non-Small Cell Lung Cancer (NSCLC), to select those suitable for treatment with Tyrosine-Kinase inhibitors (TKIs).

    Entered On: January 26 2010

    View Website

  • OCT to evaluate the microstructure of vulnerable atherosclerotic plaques

    Agency: Agenas (COTE)

    Name: C7XR

    Technology Type: Device

    Patient Indications: Optical coherence tomography (OCT) is indicated for all patients with medium-high cardiovascular risk (levels IV-VI according to the Cardiovascular Risk Chart prepared and published by the Italian National Institute of Health [ISS - Progetto Cuore]) undergoing coronary angiography.

    Entered On: January 26 2010

    View Website

  • Measurement of fractional flow reserve (FFR) by catheter pressure guide

    Agency: Agenas (COTE)

    Name: PressureWire Certus

    Technology Type: Device

    Patient Indications: Patients being treated for complex coronary artery disease

    Entered On: January 26 2010